PURPOSE: To evaluate the efficacy of gemcitabine-based chemoradiation (CT-RT) in treating patients (pts) affected by locally advanced pancreatic cancers (LAPC). METHODS AND MATERIALS: Weekly gemcitabine (100 mg/m(2)) was given as a 24-hour infusion during the course of three-dimensional radiotherapy (50.4 Gy to the tumor, 39.6 Gy to the nodes). After CT-RT, pts received five cycles of sequential chemotherapy with gemcitabine (1000 mg/m(2); 1, 8, q21). Response rate was assessed according to World Health Organization criteria 6 weeks after the end of CT-RT. Local control (LC), time to progression (TTP), metastases-free survival (MFS), and overall survival (OS) were analyzed by the Kaplan Meier method. RESULTS: Forty pts (male/female 22/18; median age 62 years, range, 36-76) were treated from 2000 to 2005. The majority had T4 tumour (n = 34, 85%), six pts (15%) had T3 tumour. Sixteen pts (40%) were node positive at diagnosis. Grade 3-4 acute toxicity was observed in 21 pts (52.5%). Thirty pts (75%) completed the treatment schedule. A clinical response was achieved in 12 pts (30%). With a median follow-up of 76 months (range, 32-98), 2-year LC was 39.6% (median, 12 months), 2-year TTP was 18.4% (median, 10 months), and 2-year MFS was 29.7% (median, 10 months). Two-year OS (25%; median, 15.5 months) compared with our previous study on 5-fluorouracil-based CT-RT (2.8%) was significantly improved (p <0.001). CONCLUSIONS: Gemcitabine CT-RT seems correlated with improved outcomes. Healthier patients who are likely to complete the treatment schedule may benefit most from this therapy. Copyright (c) 2010 Elsevier Inc. All rights reserved.
PURPOSE: To evaluate the efficacy of gemcitabine-based chemoradiation (CT-RT) in treating patients (pts) affected by locally advanced pancreatic cancers (LAPC). METHODS AND MATERIALS: Weekly gemcitabine (100 mg/m(2)) was given as a 24-hour infusion during the course of three-dimensional radiotherapy (50.4 Gy to the tumor, 39.6 Gy to the nodes). After CT-RT, pts received five cycles of sequential chemotherapy with gemcitabine (1000 mg/m(2); 1, 8, q21). Response rate was assessed according to World Health Organization criteria 6 weeks after the end of CT-RT. Local control (LC), time to progression (TTP), metastases-free survival (MFS), and overall survival (OS) were analyzed by the Kaplan Meier method. RESULTS: Forty pts (male/female 22/18; median age 62 years, range, 36-76) were treated from 2000 to 2005. The majority had T4 tumour (n = 34, 85%), six pts (15%) had T3 tumour. Sixteen pts (40%) were node positive at diagnosis. Grade 3-4 acute toxicity was observed in 21 pts (52.5%). Thirty pts (75%) completed the treatment schedule. A clinical response was achieved in 12 pts (30%). With a median follow-up of 76 months (range, 32-98), 2-year LC was 39.6% (median, 12 months), 2-year TTP was 18.4% (median, 10 months), and 2-year MFS was 29.7% (median, 10 months). Two-year OS (25%; median, 15.5 months) compared with our previous study on 5-fluorouracil-based CT-RT (2.8%) was significantly improved (p <0.001). CONCLUSIONS:Gemcitabine CT-RT seems correlated with improved outcomes. Healthier patients who are likely to complete the treatment schedule may benefit most from this therapy. Copyright (c) 2010 Elsevier Inc. All rights reserved.
Authors: Laura Raftery; Joel E Tepper; Richard M Goldberg; A William Blackstock; Mebea Aklilu; Stephen A Bernard; Anastasia Ivanova; Janine M Davies; Bert H O'Neil Journal: Am J Clin Oncol Date: 2013-06 Impact factor: 2.339
Authors: Gian Carlo Mattiucci; Luca Boldrini; Alessia Nardangeli; Andrea D'Aviero; Milly Buwenge; Francesco Cellini; Francesco Deodato; Nicola Dinapoli; Vincenzo Frascino; Gabriella Macchia; Alessio Giuseppe Morganti; Vincenzo Valentini Journal: J Cancer Res Clin Oncol Date: 2020-10-01 Impact factor: 4.553
Authors: Walid L Shaib; Andrew Ip; Kenneth Cardona; Olatunji B Alese; Shishir K Maithel; David Kooby; Jerome Landry; Bassel F El-Rayes Journal: Oncologist Date: 2016-02-01
Authors: Mashaal Dhir; Gautam K Malhotra; Davendra P S Sohal; Nicholas A Hein; Lynette M Smith; Eileen M O'Reilly; Nathan Bahary; Chandrakanth Are Journal: World J Surg Oncol Date: 2017-10-10 Impact factor: 2.754
Authors: Jakob Liermann; Marc Munter; Patrick Naumann; Amir Abdollahi; Robert Krempien; Juergen Debus Journal: Clin Transl Radiat Oncol Date: 2022-03-09
Authors: Shouki Bazarbashi; Mahmoud A Elshenawy; Ahmed Badran; Ali Aljubran; Ahmed Alzahrani; Hadeel Almanea; Abdullah Alsuhaibani; Ahmed Alashwah; Mohamed Neimatallah; Alaa Abduljabbar; Luai Ashari; Samar Alhomoud; Hazem Ghebeh; Tusneem Elhassan; Nasser Alsanea; Mohammed Mohiuddin Journal: Cancer Med Date: 2022-02-10 Impact factor: 4.711